New gene therapy could slow vision loss in rare childhood blindness

NCT ID NCT05616793

Recruiting now Disease control Sponsor: Opus Genetics, Inc Source: ClinicalTrials.gov ↗

First seen Jan 06, 2026 · Last updated May 21, 2026 · Updated 20 times

Summary

This study tests a gene therapy called OPGx-001 for people with vision loss caused by LCA5 gene mutations. The therapy is injected under the retina to help preserve sight. The trial includes 22 participants aged 4 and older and will check safety and whether vision stabilizes or improves.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LCA5 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Retina Foundation of the Southwest
RECRUITING

Dallas, Texas, 75231, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
University of Pennsylvania Perelman School of Medicine
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

LCA5